Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A

Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A

SSSE:603811
6.52
CNY
0.00
(0.00%)
0.43EPS
16.54P/E
3.20BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.77
0.93
0.92
0.94
1.12
1.19
1.49
1.66
1.51
1.42
1.47
1.55
1.81
1.85
Basic EPS, GAAP
0.11
0.16
0.17
0.2
0.23
0.21
0.29
0.36
0.37
0.35
0.36
0.44
0.44
0.42
Free Cash Flow per Basic Share
0.07
0.17
0.19
0.21
0.1
-0.3
-0.01
0.07
0.02
-0.19
0.27
0.32
0.52
- -
Dividend per Share
0.11
0.06
0.13
0.14
0.12
0.08
0.08
0.11
0.14
0.15
0.16
0.17
0.19
0.22
Book Value per Share
0.59
0.72
0.76
0.82
1.31
1.44
1.65
1.91
2.15
2.37
2.6
2.75
3.03
3.26
Tangible Book Value per Share
0.53
0.65
0.69
0.75
1.25
1.34
1.56
1.74
1.99
2.22
2.46
2.61
2.92
3.14
Basic Weighted Avg Shares
344
345
345
343
306
460
456
456
459
462
456
461
448
448
Sales/Revenue/Turnover
266
320
317
321
341
546
681
758
694
655
672
714
812
830
Operating Margin (%)
17.56
21.7
22.23
23.65
22.69
20.01
23.03
24.42
23.73
20.76
20.37
19.76
22.84
21.51
Depreciation Expense
13
16
16
16
16
19
22
48
55
62
78
96
95
- -
Net Income, GAAP
36
54
58
68
69
97
131
165
171
162
163
201
195
189
Effective Tax Rate (%)
14.25
17.22
15.34
13.95
15.89
13.73
14.37
12.68
13.3
1.62
6.9
7.95
11.78
8.45
Profit Margin (%)
13.72
16.82
18.21
21.22
20.31
17.76
19.29
21.78
24.61
24.67
24.25
28.09
24.02
22.8
Working Capital
33
67
83
99
396
206
115
55
41
179
175
102
129
237
LT Debt
- -
- -
- -
- -
- -
- -
- -
81
61
336
317
139
6
25
Total Equity
201
247
260
280
600
674
769
886
999
1,091
1,197
1,265
1,398
1,500
Return on Invested Capital (%)
12.22
18.45
19.23
22.21
14.6
15.11
18.03
18.34
15.75
12.08
10.22
12.87
13.31
- -
Return on Capital (%)
15.48
20.84
21.43
23.86
15.55
15.25
18.21
19
16.18
12.83
11.27
13.44
13.38
- -
Return on Common Equity (%)
19.23
24.02
22.77
25.24
15.74
15.38
18.54
20.26
18.36
15.58
14.29
16.37
14.72
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
32
42
30
LT Borrowings
23
25
25
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
458
458
458
Market Capitalization
3,882
3,446
3,203

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
464
447
456
Cash, Cash Equivalents & STI
269
166
206
Accounts Receivable, Net
42
35
21
Inventories
117
110
132
Total Current Liabilities
266
267
219
Payables & Accruals
- -
- -
- -
ST Debt
32
42
30
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.14%
9.57%
10.49%
Free Cash Flow
-329.73%
-252.61%
61.14%
Net Income, GAAP
14.02%
3.85%
-2.78%
Sales/Revenue/Turnover
11.22%
1.71%
13.72%
Total Cash Common Dividend
7.42%
9.9%
8.84%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
153
203
165
194
714
2025
186
231
- -
215
812
2026
201
231
182
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.1
0.09
0.19
0.44
2025
0.1
0.15
- -
0.12
0.44
2026
0.1
0.11
0.09
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.15
0.01
- -
0.17
2025
- -
0.18
- -
- -
0.19
2026
- -
0.22
- -
- -
- -

Company Description

CEO
Chun Jian Zhao
Full Time Employees
604
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building 20, Shenhong Road Minhang SH China 201100
IPO Date
Mar 15, 2017
Business
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (603811.SS) engages in the research, development, production and sale of pharmaceuticals and health products with a focus on marine biopharmaceuticals; the company manufactures active pharmaceutical ingredients (APIs) including glucosamine hydrochloride, gastrodin, ribavirin and azathioprine; finished dosage forms such as injections (e.g., torasemide injection, hydrochloride dopamine-betahistine injection), capsules, tablets, granules and external medicines; and over 90 types of products covering arthritis treatments, diuretics, brain nerve soothing, anti-virus and anti-tumor therapies. Founded in 1966 as Wenzhou No. 3 Pharmaceutical Factory and renamed in April 2001, the company is headquartered in Shanghai with primary operations in Wenzhou, Zhejiang province, China; it serves domestic markets through a Shanghai marketing center, 14 regional offices and three provincial sales departments while exporting to over 20 countries in Europe, America, India, South Africa and Southeast Asia. Products hold international certifications from U.S. FDA, EU EMEA, Australia TGA, UK MHRA and Mexico COFEPRIS; the company operates GMP-standard workshops and pursues a "Two Strengths and One Scale" initiative for Asia's largest glucosamine API (2,000 tons annually) and super fish oil (1,000 tons) production base during the 14th Five-Year Plan. Recent developments include approval of fish oil EPA soft capsules in September 2025, adding a key marine biomedicine product with ongoing distributor recruitment; completion of a 2024 share repurchase of 2.94% of shares (9.62 million shares); finalization in October 2025 of an asset sale to Ninghuai Pushun for RMB 114 million involving land transfer; passage of consistency evaluation for hydrochloride dopamine-betahistine injection; and a June 2024 asset acquisition by subsidiary Jiangsu Chengyi Pharmaceutical in Huai'an City.